Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: The Fremantle Diabetes Study

Diabetic Medicine

Volumn 25, Issue 10, 2008, Pages 1245-1250

  Myhill, P ^a   Davis, W A ^a   Bruce, D G ^a   MacKay, I R ^b   Zimmet, P ^c   Davis, T M E ^a  

^a FREMANTLE HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Cardiovascular disease; Latent autoimmune diabetes of adults; Microvascular disease; Mortality

Indexed keywords

GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE ANTIBODY;

ADULT; AGED; ARTICLE; CEREBROVASCULAR DISEASE; COMMUNITY CARE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART DISEASE; HOSPITAL ADMISSION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MICROALBUMINURIA; MORTALITY; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROPORTIONAL HAZARDS MODEL; RETINOPATHY; RISK FACTOR; TIME SERIES ANALYSIS;

AGED; ALBUMINURIA; AUTOANTIBODIES; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; GLUTAMATE DECARBOXYLASE; HEART DISEASES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; VICTORIA;

EID: 53349128949     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2008.02562.x     Document Type: Article

References (30)

1. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995 18 : 1557 1565.
2. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A et al. Clinical and genetic characteristics of Type 2 diabetes with and without GAD antibodies. Diabetes 1999 48 : 150 157.
3. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in Type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997 350 : 1288 1293.
4. Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S, Mackay IR. Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med 2000 17 : 667 674.
5. Romkens TE, Kusters GC, Netea MG, Netten PM. Prevalence and clinical characteristics of insulin-treated, anti-GAD-positive, Type 2 diabetic subjects in an outpatient clinical department of a Dutch teaching hospital. Neth J Med 2006 64 : 114 118.
6. Brophy S, Brunt H, Davies H, Mannan S, Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev 2007 CD006165.
7. Arikan E, Sabuncu T, Ozer EM, Hatemi H. The clinical characteristics of latent autoimmune diabetes in adults and its relation with chronic complications in metabolically poor controlled Turkish patients with Type 2 diabetes mellitus. J Diabetes Complications 2005 19 : 254 258.
8. Balme M, McAllister I, Davis WA, Davis TM. Retinopathy in latent autoimmune diabetes of adults: the Fremantle Diabetes Study. Diabet Med 2002 19 : 602 605.
9. Isomaa B, Almgren P, Henricsson M, Taskinen MR, Tuomi T, Groop L et al. Chronic complications in patients with slowly progressing autoimmune Type 1 diabetes (LADA). Diabetes Care 1999 22 : 1347 1353.
10. Li X, Yang L, Zhou Z, Huang G, Yan X. Glutamic acid decarboxylase 65 autoantibody levels discriminate two subtypes of latent autoimmune diabetes in adults. Chin Med J (Engl) 2003 116 : 1728 1732.
11. Owen KR, Stride A, Ellard S, Hattersley AT. Etiological investigation of diabetes in young adults presenting with apparent Type 2 diabetes. Diabetes Care 2003 26 : 2088 2093.
12. Vinik AI, Leichter SB, Pittenger GL, Stansberry KB, Holland MT, Powers AC et al. Phospholipid and glutamic acid decarboxylase autoantibodies in diabetic neuropathy. Diabetes Care 1995 18 : 1225 1232.
13. Davis TM, Yeap BB, Davis WA, Bruce DG. Lipid-lowering therapy and peripheral sensory neuropathy in Type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2008 51 : 562 566.
14. Verge CF, Stenger D, Bonifacio E, Colman PG, Pilcher C, Bingley PJ et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in Type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes 1998 47 : 1857 1866.
15. Davis TM, Bruce DG, Davis WA. Prevalence and prognostic implications of the metabolic syndrome in community-based patients with Type 1 diabetes: The Fremantle Diabetes Study. Diabetes Res Clin Pract 2007 78 : 412 417.
16. Davis WA, Norman PE, Bruce DG, Davis TM. Predictors, consequences and costs of diabetes-related lower extremity amputation complicating Type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2006 49 : 2634 2641.
17. Holman CD, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999 23 : 453 459.
18. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
19. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 1991 34 : 877 890.
20. Davis WA, Knuiman MW, Hendrie D, Davis TME. Determinants of diabetes-attributable non-blood glucose-lowering medication costs for Type 2 diabetes: The Fremantle Diabetes Study. Diabetes Care 2005 28 : 329 336.
21. Therneau TM, Grambsch PM. Testing proportional hazards. In : Therneau TM, Grambsch PM, eds. Modeling Survival Data: Extending the Cox Model. New York : Springer-Verlag, 2000 : 127 152.
22. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, Colman PG et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 2005 48 : 2206 2212.
23. Baum P, Hermann W, Verlohren HJ, Wagner A, Lohmann T, Grahmann F. Diabetic neuropathy in patients with 'latent autoimmune diabetes of the adults' (LADA) compared with patients with Type 1 and Type 2 diabetes. J Neurol 2003 250 : 682 687.
24. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in Type 2 diabetes: the UK Prospective Diabetes Study (UKPDS 64). Kidney Int 2003 63 : 225 232.
25. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in Type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 2001 60 : 219 227.
26. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with Type 1 diabetes: inception cohort study. Br Med J 2004 328 : 1105.
27. Zimmet PZ, Shaten BJ, Kuller LH, Rowley MJ, Knowles WJ, Mackay IR. Antibodies to glutamic acid decarboxylase and diabetes mellitus in the Multiple Risk Factor Intervention Trial. Am J Epidemiol 1994 140 : 683 690.
28. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with Type 2 diabetes in North America and Europe. Diabetes 2004 53 : 3193 200.
29. Norman PE, Semmens JB, Laurvick CL, Lawrence-Brown M. Long-term relative survival in elderly patients after carotid endarterectomy: a population-based study. Stroke 2003 34 : 95 98.
30. Bradshaw PJ, Jamrozik K, Jelfs P, Le M. Mobile Australians: a moving target for epidemiologists. Med J Aust 2000 172 : 566.